EFFECTIVENESS OF AFINITOR® (EVEROLIMUS) FOR METASTATIC KIDNEY CANCER


Cite item

Full Text

Abstract

Therapeutic agents targeting tyrosine kinase of vascular endothelial growth factor receptors (VEGFR) or their's ligands allowed to archieve the significant results in treatment of patients with advanced renal cell carcinoma. Investigations of rapamycin and it's cell target wre the first step to new class of drug development, they have been called as mTOR inhibitors. Currently mTOR inhibitors are the agents of investigations in a big number of phase II-III clinical trials in multiple tumor types. mTOR inhibitor everolimus acts through key pathways and targets key pathogenetic mechanisms of renal cell carcinoma. mTOR inhibitor everolimus (Afinitor®) has proven clinical efficacy in renal cancer and well-tolerated by almost patients. Today this drug is successfully used in more than 50 countries worlwide for treatment of patients with advanced and/or metastatic renal cell carcinoma after failure on or after any other antiangiogenic therapy.

References

  1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
  2. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-30.
  3. Seelinger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumour systems: a therapeutical target against primary tumour growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007;26(3-4):611-21.
  4. Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13(2 Suppl.):758-63.
  5. Yuan R, Kay A, Berg WJ. et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45.
  6. Алексеев Б.Я., Калпинский А.С. Эверолимус в лечении метастатического рака почек // Онкоурология. 2010. № 3. С. 19-24.
  7. Cohen H, McGovern F. Renal cell carcinoma. N Engl J Med 2005;353:3477-90.
  8. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6.
  9. Larkin JMG, Kipps ELS, Powell CJ, et al. Review: systemic therapy for advanced renal cell carcinoma. Ther Advanc Med Oncol 2009;1:15-27.
  10. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
  11. Patard J-J. New treatment options for renal cell cancer - critical evaluation. Eur Urol 2008;(Suppl. 7):443-6.
  12. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
  13. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13:3109-14.
  14. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.
  15. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2007;13(Suppl. 2):680-4.
  16. Brugarolas J. Renal-cell carcinoma - Molecular pathways and therapies. N Engl J Med 2007;356(2):185-7.
  17. De Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765-73.
  18. O'Donnell A, Faivre S, Burris HA. III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95.
  19. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008;26(10):1596-602.
  20. Jac J, Giessinger S, Khan M, et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). 2007ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25:5107.
  21. Jac J, Amato RJ, Giessinger S, et al. A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:5113.
  22. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
  23. Motzer RJ, Kay A, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [Abstr 278].
  24. Whorf RC, Hainsworth JD, Spigel DR, et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008;26:5010.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies